

Attention Business Editors:  
Welichem Announced Change of Board Members

BURNABY, BC, Jan. 25 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Mr. Weihe Wang and Mr. Zhaofang Zhang resigned as directors of the Company and that Mr. Wenfeng Liu and Ms. Mingrong Lu joined the Company as directors, effective January 24, 2008. The Company would like to thank Mr. Wang and Mr. Zhang for their valued contribution to the Company.

Mr. Liu is a very successful entrepreneur and is Chairman of the Board and a founding shareholder of Hebei Wenfeng Iron and Steel Co. Ltd. He has held senior management and executive positions in various companies in China. Mr. Liu is a principal of Canadian Maple Leaf Investment Ltd. (CMLI) that is one of the major shareholders of the Company.

Ms. Lu is a very successful entrepreneur and a founding shareholder of Hebei Wenfeng Iron and Steel Co. Ltd. She has held management and executive positions in several companies in China. Ms. Lu is also a principal of Canadian Maple Leaf Investment Ltd. (CMLI).

Dr. Hugh Wynne-Edwards, Chairman, stated "We are very pleased to have Mr. Liu and Ms. Lu as members of our Board at this exciting stage of development of the Company. They bring to the Company a wealth of experience in business development and in raising capital, which is valuable for the success of our Company."

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD

York Yingping Guo  
President & Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

%SEDAR: 00021386E

/For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:  
yorkguo(at)welichem.com/  
(WBI.)

CO: Welichem Biotech Inc.

CNW 13:26e 25-JAN-08